Literature DB >> 19903862

Influence of glucosamine on glomerular mesangial cell turnover: implications for hyperglycemia and hexosamine pathway flux.

Leighton R James1, Catherine Le, James W Scholey.   

Abstract

Cells exposed to high glucose may undergo hypertrophy, proliferation, and apoptosis, but the role of hexosamine flux in mediating these effects has not been fully elucidated. Accordingly, we studied the effects of glucose and glucosamine on rat glomerular mesangial cells (MC) turnover. Compared with physiological glucose (5.6 mM), treatment with high glucose (25 mM) for 24 h stimulated MC proliferation, an effect that was mimicked by exposure to low concentrations of glucosamine (0.05 mM). The percentage of cells in G(0)/G(1) phase of the cell cycle was reduced with a concomitant increase of the number of cells in G(2)/M phase. Proliferating cell nuclear antigen, phosphorylated mammalian target of rapamycin [phospho-mTOR (Ser(2448))], and total regulatory-associated protein of mTOR were increased by high glucose and glucosamine treatment. Inhibition of glutamine:fructose-6-phosphate amidotransferase (GFAT), the rate-limiting enzyme for hexosamine flux, with 6-diazo-5-oxonorleucine (10 muM) and of mTOR with rapamycin both attenuated glucose-mediated MC proliferation. Higher glucosamine concentrations (0.25-10 mM) caused MC apoptosis after 48 h, and, in addition, GFAT overexpression also increased MC apoptosis (TdT-dUTP nick end-labeling-positive cells: 3.8 +/- 0.3 vs. 1.1 +/- 0.2% for empty vector; P < 0.05). Hence, hexosamine flux is an important determinant of MC proliferation and apoptosis. The proliferative response to high glucose and hexosamine flux is rapamycin-sensitive, suggesting that this effect is associated with signaling through rapamycin-sensitive mTOR complex 1 (mTORC1).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903862      PMCID: PMC2822474          DOI: 10.1152/ajpendo.00232.2009

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  72 in total

1.  Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

Authors:  Yi Yang; Jingjing Wang; Ling Qin; Zhangfei Shou; Jie Zhao; Huiping Wang; Ying Chen; Jianghua Chen
Journal:  Am J Nephrol       Date:  2007-07-20       Impact factor: 3.754

Review 2.  PCNA, the maestro of the replication fork.

Authors:  George-Lucian Moldovan; Boris Pfander; Stefan Jentsch
Journal:  Cell       Date:  2007-05-18       Impact factor: 41.582

3.  Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc.

Authors:  Voraratt Champattanachai; Richard B Marchase; John C Chatham
Journal:  Am J Physiol Cell Physiol       Date:  2006-08-09       Impact factor: 4.249

4.  Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.

Authors:  Luciana E Giono; James J Manfredi
Journal:  Mol Cell Biol       Date:  2007-03-19       Impact factor: 4.272

5.  Homocysteine induces mesangial cell apoptosis via activation of p38-mitogen-activated protein kinase.

Authors:  S Shastry; A J Ingram; J W Scholey; L R James
Journal:  Kidney Int       Date:  2006-12-06       Impact factor: 10.612

6.  Phenotype-specific inhibition of the vascular smooth muscle cell cycle by high glucose treatment.

Authors:  X-L Zheng; S-G Yuan; D-Q Peng
Journal:  Diabetologia       Date:  2007-02-14       Impact factor: 10.122

Review 7.  Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins.

Authors:  Gerald W Hart; Michael P Housley; Chad Slawson
Journal:  Nature       Date:  2007-04-26       Impact factor: 49.962

Review 8.  Targeting the mTOR signaling network in cancer.

Authors:  Gary G Chiang; Robert T Abraham
Journal:  Trends Mol Med       Date:  2007-10-01       Impact factor: 11.951

Review 9.  Hexosamine biosynthesis and protein O-glycosylation: the first line of defense against stress, ischemia, and trauma.

Authors:  John C Chatham; Laszlo G Nöt; Norbert Fülöp; Richard B Marchase
Journal:  Shock       Date:  2008-04       Impact factor: 3.454

Review 10.  The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.

Authors:  Robert T Abraham; James J Gibbons
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

View more
  2 in total

Review 1.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

2.  AS101 prevents diabetic nephropathy progression and mesangial cell dysfunction: regulation of the AKT downstream pathway.

Authors:  Itay Israel Shemesh; Benaya Rozen-Zvi; Yona Kalechman; Uzi Gafter; Benjamin Sredni
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.